Latest Breaking News On - Immunologic diseases - Page 4 : vimarsana.com
Vividion Therapeutics Announces Formation of Scientific Advisory Board
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: The 2021 John Dystel Prize for Multiple Sclerosis Research goes to Vijay K. Kuchroo, DVM, PhD, the Samuel Wasserstrom Professor of Neurology at Harvard Medical School, for outstanding research contributions. view more
Credit: Brigham and Women s Hospital
NEW YORK, April 13, 2021 Vijay K. Kuchroo, DVM, PhD, the Samuel Wasserstrom Professor of Neurology at Harvard Medical School, has been selected as the 2021 recipient of the John Dystel Prize for Multiple Sclerosis Research.
A graduate of Veterinary Medicine from the College of Veterinary Medicine in Hisar, India, who earned a PhD in pathology at the University of Queensland in Brisbane Australia, Kuchroo is Senior Scientist at Brigham and Women s Hospital, and Co-director of the Center for Infection and Immunity, Brigham Research Institute, Boston. He is a member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation and is the founding
Laser Approach May Improve Anti-Tumor Therapies
azooptics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azooptics.com Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - Use of a cosmetic laser invented at Massachusetts General Hospital (MGH) may improve the effectiveness of certain anti-tumor therapies and extend their use to more diverse forms of cancer. The strategy was tested and validated in mice, as described in a study published in
Immune checkpoint inhibitors are important medications that boost the immune system s response against various cancers, but only certain patients seem to benefit from the drugs. The cancer cells of these patients often have multiple mutations that can be recognized as foreign by the immune system, thereby inducing an inflammatory response.
In an attempt to expand the benefits of immune checkpoint inhibitors for additional patients, a team led by David E. Fisher, MD, PhD, director of the Mass General Cancer Center s Melanoma Program and director of MGH s Cutaneous Biology Research Center, conducted experiments in mice with a poorly immunogenic melanoma that is not hindered by immune checkpoint i